Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension

Hypertension. 1997 Jan;29(1 Pt 2):274-9. doi: 10.1161/01.hyp.29.1.274.

Abstract

To evaluate whether cyclooxygenase constrictor substances can impair nitric oxide-mediated vasodilation in essential hypertension, in seven normotensive subjects (43.3 +/- 4.1 years; BP, 117 +/- 6/81 +/- 2 mm Hg) and seven essential hypertensive patients (47.1 +/- 5.2 years; BP, 151 +/- 8/98 +/- 4 mm Hg) we studied forearm blood flow (strain-gauge plethysmography) modifications induced by intrabrachial acetylcholine (0.15, 0.45, 1.5, 4.5, 15 micrograms.100 mL-1.min-1) in basal conditions, during infusion of NG-monomethyl-L-arginine (L-NMMA; 100 micrograms.100 mL-1.min-1), a nitirc oxide synthase inhibitor, or indomethacin (50 micrograms.100 mL-1.min-1), a cyclooxygenase inhibitor, or simultaneous indomethacin and L-NMMA. In normotensives, vasodilation to acetylcholine was blunted by L-NMMA (maximum flow increase: 671 +/- 64% and 386 +/- 42%, respectively; P < .01), and this effect was unchanged by indomethacin. In contrast, in hypertensive patients, vasodilation to acetylcholine (maximum flow increase: 458 +/- 33%) was unchanged by L-NMMA. Indomethacin significantly (P < .01) increased the response to acetylcholine (maximum flow increase: 635 +/- 53%) and restored the inhibitory effect of L-NMMA (maximum flow increase: 445 +/- 36%; P < .01 versus indomethacin alone). In an adjunctive seven normotensives (51.4 +/- 4.2 years; BP, 114 +/- 5/79 +/- 3 mm Hg) and seven essential hypertensives (53.2 +/- 7.6 years; BP, 153 +/- 9/100 +/- 3 mm Hg) we repeated the same protocol by replacing L-NMMA with L-arginine (200 micrograms.100 mL-1.min-1), the substrate for NO synthase. In normotensives, vasodilation to acetylcholine was increased by L-arginine (maximum flow increase: 539 +/- 48% and 806 +/- 61%, respectively) and this effect was unchanged by indomethacin. In hypertensive patients, vasodilation to acetylcholine (maximum flow increase: 339 +/- 32%) was unchanged by L-arginine but was significantly (P < .01) increased by indomethacin (maximum flow increase: 592 +/- 38%). Moreover, indomethacin restored the facilitatory effect of L-arginine (maximum flow increase: 804 +/- 56%; P < .01 versus indomethacin alone). Therefore, cyclooxygenase inhibition restores nitric oxide-mediated vasodilation in essential hypertension, suggesting that cyclooxygenase-dependent substances can impair nitric oxide production.

MeSH terms

  • Acetylcholine / antagonists & inhibitors
  • Acetylcholine / pharmacology*
  • Arginine / pharmacology
  • Cyclooxygenase Inhibitors / pharmacology*
  • Female
  • Forearm / blood supply
  • Humans
  • Hypertension / physiopathology*
  • Indomethacin / pharmacology*
  • Male
  • Middle Aged
  • Nitric Oxide / antagonists & inhibitors
  • Nitric Oxide / physiology*
  • Nitroprusside / pharmacology*
  • Regional Blood Flow / drug effects
  • Vasodilation / drug effects*
  • Vasodilation / physiology
  • Vasodilator Agents / antagonists & inhibitors
  • Vasodilator Agents / pharmacology*
  • omega-N-Methylarginine / pharmacology*

Substances

  • Cyclooxygenase Inhibitors
  • Vasodilator Agents
  • Nitroprusside
  • omega-N-Methylarginine
  • Nitric Oxide
  • Arginine
  • Acetylcholine
  • Indomethacin